← FDA ENFORCEMENT
D-0505-2024Class II

Preferred Pharmaceuticals, Inc.

Recalling firm
Preferred Pharmaceuticals, Inc.
Product type
Drug
Status
Ongoing
Report date
2024-05-29
Distribution
Product distributed to CA, FL, OK, KS and CT
Firm state
CA
Product quantity
66 bottles of 30 tablets
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Validation & Qualification
Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Product description

Duloxetine Delayed-Release Cap USP 30mg, 30-count bottle, Rx only, Preferred Pharmaceutcals, Inc., NDC 68788-9301-03

Code / lot info

Lot #: J2022G, Exp: 01/01/2025

Other recalls SPEQ maps to Validation & Qualification
2026-07-22Class IIBell Pharmaceuticals, Inc2026-07-22Class IIBell Pharmaceuticals, Inc2026-07-22Class IIBell Pharmaceuticals, Inc2026-07-22Class IIBell Pharmaceuticals, Inc
See all Validation & Qualification recalls →

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.